PMID- 28781337
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180514
IS  - 1349-3329 (Electronic)
IS  - 0040-8727 (Linking)
VI  - 242
IP  - 4
DP  - 2017 Aug
TI  - The 5A Allele of the MMP3-Gene Promoter Polymorphism Is a Risk Factor for Poor 
      Outcome of Hemodialysis Patients.
PG  - 273-279
LID - 10.1620/tjem.242.273 [doi]
AB  - Cardiovascular morbidity is the leading cause of death in dialysis patients and 
      many risk factors have been involved in its pathogenesis. Genetic susceptibility 
      may be of importance including polymorphism for matrix metalloproteinase 3 
      (MMP3), which is an enzyme that catalyzes the degradation of collagen, 
      proteoglycans, fibronectin, laminine and elastin. The MMP3 gene promoter contains 
      an insertion/deletion polymorphism characterised by an array of 5 or 6 adenosine 
      residues (5A/6A) at -1612 position. Literature data show that the 5A or 6A allele 
      of the MMP3 gene shows different risk for cardiovascular and overall outcome in 
      general population. The aim was to analyze the -1612 5A/6A promoter polymorphism 
      in a group of hemodialysis patients and to correlate the findings with 
      cardiovascular morbidity and 7-year all-cause and cardiovascular mortality. This 
      study included 196 patients on hemodialysis for longer than six months at 
      University Medical Center Zvezdara. The leading causes of end stage renal disease 
      were hypertension and diabetes mellitus. Venous blood was collected on midweek 
      dialysis session and genotype analysis was performed by using polymerase chain 
      reaction-restriction fragment length polymorphism method. Among the 198 
      hemodialysis patients, there were 142 (72%) 5A/6A heterozygotes, 12 (6%) 5A/5A 
      homozygotes, and 44 (22%) 6A/6A homozygotes. These data are consistent with 
      Hardy-Weinberg equilibrium. After 7-year follow-up, the 5A homozygotes showed the 
      lowest all-cause and cardiovascular survival, while the 6A homozygotes showed the 
      highest cardiovascular survival. The 5A allele of the MMP3-gene promoter 
      polymorphism is a potential risk factor in the poor outcome of hemodialysis 
      patients.
FAU - Dragovic, Jelena Tosic
AU  - Dragovic JT
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
FAU - Popovic, Jovan
AU  - Popovic J
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
FAU - Djuric, Petar
AU  - Djuric P
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
FAU - Bulatovic, Ana
AU  - Bulatovic A
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
FAU - Jankovic, Aleksandar
AU  - Jankovic A
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
FAU - Buzadzic, Ivana
AU  - Buzadzic I
AD  - Departmant of Human Genetics and Prenatal Diagnostics, Zvezdara University 
      Medical Center.
FAU - Dimkovic, Nada
AU  - Dimkovic N
AD  - Clinical Department for Renal Diseases, Zvezdara University Medical Center.
AD  - Faculty of Medicine, University of Belgrade.
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - *Alleles
MH  - Cardiovascular Diseases/epidemiology
MH  - Female
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Matrix Metalloproteinase 3/*genetics
MH  - Middle Aged
MH  - Morbidity
MH  - *Polymorphism, Genetic
MH  - *Promoter Regions, Genetic
MH  - *Renal Dialysis
MH  - Risk Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - cardiovascular morbidity
OT  - gene polymorphism
OT  - hemodialysis
OT  - matrix metalloproteinase
OT  - mortality
EDAT- 2017/08/07 06:00
MHDA- 2018/05/15 06:00
CRDT- 2017/08/08 06:00
PHST- 2017/08/08 06:00 [entrez]
PHST- 2017/08/07 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
AID - 10.1620/tjem.242.273 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2017 Aug;242(4):273-279. doi: 10.1620/tjem.242.273.